62,803 Shares in Veeva Systems Inc. $VEEV Purchased by ABN Amro Investment Solutions

ABN Amro Investment Solutions purchased a new stake in Veeva Systems Inc. (NYSE:VEEV) during the second quarter, according to its most recent filing with the SEC. The firm purchased 62,803 shares of the technology company’s stock, valued at approximately $18,086,000.

Several other hedge funds have also modified their holdings of VEEV. Nuveen LLC acquired a new stake in shares of Veeva Systems in the 1st quarter worth $365,684,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Veeva Systems by 20.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,992,372 shares of the technology company’s stock valued at $924,754,000 after purchasing an additional 689,700 shares in the last quarter. Los Angeles Capital Management LLC increased its stake in shares of Veeva Systems by 423.8% in the 2nd quarter. Los Angeles Capital Management LLC now owns 841,303 shares of the technology company’s stock valued at $242,278,000 after purchasing an additional 680,702 shares in the last quarter. Linonia Partnership LP raised its stake in shares of Veeva Systems by 52.7% during the 1st quarter. Linonia Partnership LP now owns 1,836,557 shares of the technology company’s stock worth $425,402,000 after buying an additional 633,585 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Veeva Systems by 48.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,799,931 shares of the technology company’s stock valued at $416,918,000 after acquiring an additional 585,785 shares during the period. 88.20% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on VEEV shares. TD Cowen raised shares of Veeva Systems from a “hold” rating to a “buy” rating and boosted their target price for the stock from $297.00 to $380.00 in a research note on Tuesday, October 7th. UBS Group lifted their target price on shares of Veeva Systems from $285.00 to $310.00 and gave the stock a “neutral” rating in a research note on Thursday, August 28th. Piper Sandler increased their target price on shares of Veeva Systems from $325.00 to $355.00 and gave the company an “overweight” rating in a research report on Thursday, August 28th. Wall Street Zen lowered shares of Veeva Systems from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Wells Fargo & Company upped their price objective on shares of Veeva Systems from $300.00 to $326.00 and gave the company an “overweight” rating in a research note on Tuesday, August 26th. Seventeen research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $307.58.

Insider Buying and Selling at Veeva Systems

In related news, SVP Jonathan Faddis sold 720 shares of the stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $298.12, for a total transaction of $214,646.40. Following the transaction, the senior vice president owned 7,868 shares of the company’s stock, valued at approximately $2,345,608.16. This represents a 8.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of Veeva Systems stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the completion of the transaction, the insider owned 25,325 shares of the company’s stock, valued at $7,765,151.50. This trade represents a 19.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 24,665 shares of company stock valued at $7,438,000 over the last quarter. 10.30% of the stock is owned by company insiders.

Veeva Systems Stock Performance

Shares of Veeva Systems stock opened at $297.11 on Thursday. The stock has a 50 day moving average of $288.05 and a 200 day moving average of $276.78. The firm has a market capitalization of $48.70 billion, a price-to-earnings ratio of 61.01, a PEG ratio of 2.22 and a beta of 0.98. Veeva Systems Inc. has a fifty-two week low of $201.54 and a fifty-two week high of $310.50.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings data on Wednesday, August 27th. The technology company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.90 by ($0.64). The company had revenue of $789.08 million during the quarter, compared to analysts’ expectations of $768.49 million. Veeva Systems had a net margin of 27.29% and a return on equity of 13.72%. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.62 earnings per share. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. Analysts forecast that Veeva Systems Inc. will post 4.35 EPS for the current year.

Veeva Systems Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.